1 completed, 1 recruiting, 1 withdrawn. 3 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Completed 1, Recruiting 1, Withdrawn 1 |
Follow PF06821497: new trials by email Literature Review of PF06821497 trials Research Report on PF06821497
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Learn How Different Tablets of the Study Medicine Mevrometostat Are Taken up Into the Blood in Healthy Adults Treatment A, Treatment B, Treatment C - Healthy | Phase 1 | Withdrawn | Pfizer | 2025-04-28 | 2025-04-24 | |
| A Study to Learn How the Medicine Called [14C] PF-06821497 is Taken up Into and Removed From the Body. Oral [14C] PF-06821497, Oral PF-06821497, IV [14C] PF-06821497 - Healthy Participants | Phase 1 | Completed | Pfizer | 6 | 2024-08-30 | 2025-01-23 |
| A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma Mevrometostat (PF-06821497), Enzalutamide, Itraconazole - Metastatic Castration Resistant Prostate Cancer (mCRPC), Small Cell Lung Cancer (SCLC) | Phase 1 | Recruiting | Pfizer | 453 | 2018-04-17 | 2026-10-15 |
Lymphoma, Follicular (1) · Recurrence (1) · Small Cell Lung Carcinoma (1)
Pfizer (3)
Belgium (1) · Bulgaria (1) · China (1) · Japan (1) · Netherlands (1) · Poland (1) · Russia (1) · South Korea (1) · Spain (1) · United States (1)
2023 (2)